MX2022006877A - Uso de un abridor de canal de potasio kv7 para tratar el dolor. - Google Patents
Uso de un abridor de canal de potasio kv7 para tratar el dolor.Info
- Publication number
- MX2022006877A MX2022006877A MX2022006877A MX2022006877A MX2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A MX 2022006877 A MX2022006877 A MX 2022006877A
- Authority
- MX
- Mexico
- Prior art keywords
- treating pain
- potassium channel
- channel opener
- methods
- subject
- Prior art date
Links
- 239000004036 potassium channel stimulating agent Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Light Guides In General And Applications Therefor (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945093P | 2019-12-06 | 2019-12-06 | |
| US201962948010P | 2019-12-13 | 2019-12-13 | |
| PCT/US2020/063471 WO2021113757A1 (en) | 2019-12-06 | 2020-12-04 | Use of a kv7 potassium channel opener for treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006877A true MX2022006877A (es) | 2022-07-11 |
Family
ID=73856375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006877A MX2022006877A (es) | 2019-12-06 | 2020-12-04 | Uso de un abridor de canal de potasio kv7 para tratar el dolor. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4069211A1 (https=) |
| JP (1) | JP2023504166A (https=) |
| KR (1) | KR20220113411A (https=) |
| CN (1) | CN114786658A (https=) |
| AU (1) | AU2020397173A1 (https=) |
| BR (1) | BR112022010733A2 (https=) |
| CA (1) | CA3159436A1 (https=) |
| CL (1) | CL2022001477A1 (https=) |
| CR (1) | CR20220318A (https=) |
| IL (1) | IL293504A (https=) |
| MX (1) | MX2022006877A (https=) |
| PE (1) | PE20221169A1 (https=) |
| TW (1) | TW202133847A (https=) |
| WO (1) | WO2021113757A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110511220B (zh) | 2018-05-22 | 2022-04-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用 |
| CA3151863C (en) * | 2021-10-27 | 2024-01-02 | Shanghai Zhimeng Biopharma, Inc. | Compound as potassium channel regulator and preparation and use thereof |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915414D0 (en) * | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Medical use |
| US7553858B2 (en) * | 2003-12-17 | 2009-06-30 | Meda Pharma Gmbh & Co. Kg | Combination of flupirtine and tramadol |
| SG174095A1 (en) * | 2006-08-23 | 2011-09-29 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| WO2013067591A1 (en) * | 2011-11-10 | 2013-05-16 | Relevare Australia Pty Ltd | Topical formulations for pain management |
| US9248122B2 (en) * | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
| WO2019217924A1 (en) * | 2018-05-11 | 2019-11-14 | Xenon Pharmaceuticals Inc. | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
-
2020
- 2020-12-04 CN CN202080084722.3A patent/CN114786658A/zh active Pending
- 2020-12-04 PE PE2022001015A patent/PE20221169A1/es unknown
- 2020-12-04 MX MX2022006877A patent/MX2022006877A/es unknown
- 2020-12-04 TW TW109142937A patent/TW202133847A/zh unknown
- 2020-12-04 WO PCT/US2020/063471 patent/WO2021113757A1/en not_active Ceased
- 2020-12-04 CR CR20220318A patent/CR20220318A/es unknown
- 2020-12-04 BR BR112022010733A patent/BR112022010733A2/pt not_active Application Discontinuation
- 2020-12-04 KR KR1020227021509A patent/KR20220113411A/ko active Pending
- 2020-12-04 EP EP20828491.9A patent/EP4069211A1/en active Pending
- 2020-12-04 JP JP2022532695A patent/JP2023504166A/ja active Pending
- 2020-12-04 AU AU2020397173A patent/AU2020397173A1/en active Pending
- 2020-12-04 CA CA3159436A patent/CA3159436A1/en active Pending
- 2020-12-04 IL IL293504A patent/IL293504A/en unknown
-
2022
- 2022-06-03 CL CL2022001477A patent/CL2022001477A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3159436A1 (en) | 2021-06-10 |
| BR112022010733A2 (pt) | 2022-08-23 |
| TW202133847A (zh) | 2021-09-16 |
| WO2021113757A1 (en) | 2021-06-10 |
| CN114786658A (zh) | 2022-07-22 |
| JP2023504166A (ja) | 2023-02-01 |
| CR20220318A (es) | 2022-10-07 |
| KR20220113411A (ko) | 2022-08-12 |
| AU2020397173A1 (en) | 2022-06-23 |
| IL293504A (en) | 2022-08-01 |
| PE20221169A1 (es) | 2022-07-25 |
| CL2022001477A1 (es) | 2023-04-28 |
| EP4069211A1 (en) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013247A (es) | Metodos para potenciar la biodisponibilidad y la exposicion de un abridor de canales de potasio dependientes de voltaje. | |
| MX2022005490A (es) | Metodos para el tratamiento de trastornos depresivos. | |
| MX2022006877A (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor. | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| WO2019199861A3 (en) | Hemp extract for treatment of pain in animals | |
| MX2023009314A (es) | Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia. | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| MX2025002705A (es) | Isoquinolonas como inhibidores de pi3k | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| CA3198952A1 (en) | Gel, ointment, and foam formulations of tapinarof and methods of use | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| MX2025005318A (es) | Compuesto de cucurbiturilo y uso medico del mismo | |
| MX2025005597A (es) | Compuestos antisenescencia novedosos y composiciones de los mismos | |
| MX2024015077A (es) | Benzopirimidina-4(3h)-onas como inhibidores de pi3k | |
| GEAP202415862A (en) | Alcohol derivatives as kv7 potassium channel openers | |
| MX2023009313A (es) | Terapia conjunta para el tratamiento de trastornos convulsivos. | |
| PH12022553502A1 (en) | Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine | |
| NZ787838B2 (en) | Methods of treating depressive disorders | |
| AR026506A1 (es) | Un medicamiento para la prevencion y el tratamiento de la disfuncion sexual | |
| WO2025034812A3 (en) | Trifluoroborate (bf3) compositions for use in boron neutron capture therapy and methods thereof | |
| SE2430407A1 (en) | New composition | |
| NZ788497A (en) | Use of reboxetine to treat nervous system disorders | |
| JOP20240255A1 (ar) | مثبطات الفيروس المخلوي للجهاز التنفسي البشري وفيروس الميتانيمو | |
| SA523440604B1 (ar) | تركيبة علاجية جديدة أساسها زيوت عطرية بجرعات منخفضة |